"instanceType","uuid:ID","id","description","label","name","text"
"Objective","458e2730-34cd-4961-baa1-98ebe69a2199","Objective_1","Main objective","","OBJ1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])."
"Objective","06524247-5688-4dc2-ac4b-3e69ff8e7b5d","Objective_2","Safety","","OBJ2","To document the safety profile of the xanomeline TTS."
"Objective","a2a63d6f-ecca-43e5-9834-e0a952fbd963","Objective_3","Behaviour","","OBJ3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas."
"Objective","4e9b83da-6394-44ac-993b-be465ebade7a","Objective_4","","","OBJ4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5)."
"Objective","020eaa2c-fa13-4e13-8204-fcdbc0457c35","Objective_5","","","OBJ5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2)."
"Objective","777e1a78-2a83-4374-aa31-fd418cf4a5e2","Objective_6","","","OBJ6","To assess the treatment response as a function of Apo E genotype."
